1427 related articles for article (PubMed ID: 24316460)
1. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
[TBL] [Abstract][Full Text] [Related]
2. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
3. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
5. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
[TBL] [Abstract][Full Text] [Related]
6. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
8. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
[TBL] [Abstract][Full Text] [Related]
10. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
11. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
[TBL] [Abstract][Full Text] [Related]
12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
13. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
14. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
15. Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.
Bertz H; Spyridonidis A; Ihorst G; Engelhardt M; Grüllich C; Wäsch R; Marks R; Finke J
Biol Blood Marrow Transplant; 2012 Jun; 18(6):894-902. PubMed ID: 22108569
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
17. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients.
Seth T; Kanga U; Sood P; Sharma V; Mishra P; Mahapatra M
Transplant Proc; 2012 May; 44(4):922-4. PubMed ID: 22564586
[TBL] [Abstract][Full Text] [Related]
18. Matched sibling versus matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia: experience of the polish pediatric group for hematopoietic stem cell transplantation.
Szpecht D; Gorczyńska E; Kałwak K; Owoc-Lempach J; Choma M; Styczyński J; Goździk J; Dłużniewska A; Wysocki M; Kowalczyk JR; Chybicka A; Pieczonka A; Wachowiak J
Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):225-33. PubMed ID: 22527354
[TBL] [Abstract][Full Text] [Related]
19. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
